Glinkina L S, Bruvere R Zh
Vopr Onkol. 1992;38(6):659-66.
Changes in E-receptor-bearing T-lymphocyte level (total and that of active T-lymphocytes) were studied in peripheral blood and resected material obtained from skin malignant melanoma and gastric cancer patients treated with rigvir, an original immunomodulator of the viral origin. Injection of rigvir into peripheral blood was followed by an increase in active T-lymphocyte level and stimulated their migration into tumor. The latter was determined by stage and rate of tumor advancement.
对皮肤恶性黑色素瘤和胃癌患者外周血及切除组织中携带E受体的T淋巴细胞水平（总数及活性T淋巴细胞水平）的变化进行了研究，这些患者接受了病毒源原始免疫调节剂里格非尔（Rigvir）的治疗。将里格非尔注入外周血后，活性T淋巴细胞水平升高，并刺激它们迁移至肿瘤部位。后者由肿瘤进展的阶段和速度决定。
